Scientific Advisory Board

Judith Korner, M.D., Ph.D.

Dr. Korner currently serves as Professor of Medicine in the Department of Medicine and Division of Endocrinology and Metabolism at New York Presbyterian/ Columbia University Irving Medical Center. Her area of research expertise is focused on the pathophysiology and treatment of obesity and type 2 diabetes. She currently has funding from the National Institutes of Health (NIH) to investigate peptide hormones that control hunger and food intake, particularly in association with bariatric surgery. She was the Principal Investigator of a NIH-funded trial to study the effects of leptin administration after gastric bypass surgery on body weight and neuroendocrine function and was the Principal Investigator at Columbia University of a multi-center randomized trial of medical management vs gastric bypass surgery for the treatment of diabetes. Dr. Korner is also the Director of the Weight Control Center at Columbia University Irving Medical Center that specializes in the medical treatment of obesity or excessive weight gain. She has published original research as well as chapters and review articles on weight regulation and obesity therapy, serves as Vice Chair of the Board of Directors of the American Board of Obesity Medicine, and is a member of several professional organizations including The Obesity Society, The Endocrine Society, The American Diabetes Association, The New York Obesity Research Center and the Diabetes and Endocrinology Research Center at Columbia University. She has shared her expertise in the field of obesity through on-site training and mentoring of students and junior faculty and presentations at conferences world-wide.

James Mulé, Ph.D.

Dr. Mulé is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, KB Capital Management, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (, Journal of Immunotherapy, and Cancer Immunology Research (AACR).

Dr. Mulé received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Al to, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endo wed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.